<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/6C3712F6-BDFA-4D7B-9770-ABAEA9E72214"><gtr:id>6C3712F6-BDFA-4D7B-9770-ABAEA9E72214</gtr:id><gtr:name>Novozymes Biopharma UK Ltd</gtr:name><gtr:address><gtr:line1>Castle court</gtr:line1><gtr:line2>59 Castle Boulevard</gtr:line2><gtr:line4>Nottingham</gtr:line4><gtr:postCode>NG7 1FD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/6C3712F6-BDFA-4D7B-9770-ABAEA9E72214"><gtr:id>6C3712F6-BDFA-4D7B-9770-ABAEA9E72214</gtr:id><gtr:name>Novozymes Biopharma UK Ltd</gtr:name><gtr:address><gtr:line1>Castle court</gtr:line1><gtr:line2>59 Castle Boulevard</gtr:line2><gtr:line4>Nottingham</gtr:line4><gtr:postCode>NG7 1FD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/95FF468F-3A7C-4D7C-9442-BCDD940A5AE4"><gtr:id>95FF468F-3A7C-4D7C-9442-BCDD940A5AE4</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Caddick</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A0E55D4C-8E28-4B81-89B3-A3B08401A438"><gtr:id>A0E55D4C-8E28-4B81-89B3-A3B08401A438</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Baker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FJ010448%2F1"><gtr:id>37EB44B7-3B13-407D-8DAD-07BEBB296AD0</gtr:id><gtr:title>A New Approach to the Chemical Modification of Antibodies via Maleimide Bridging of Disulfides</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/J010448/1</gtr:grantReference><gtr:abstractText>We are entering extremely exciting times in the development of the next generation of therapeutics, as scientists have turned their attention to the manipulation of part of nature's own defense mechanism; antibodies. Antibodies can now be designed in the lab to target a variety of diseases, including cancer and infectious diseases. They represent the fastest growing class of therapeutics, with a market value estimated to be around $50 billion. Currently however, a limiting factor in the area is the lack of reliable chemical methods that will allow the modification and optimisation of the properties of antibodies. We are proposing here to exemplify a new class of chemical reagents that will allow the highly effective modification of antibodies for the first time. This exemplification will enable us to establish partnerships with pharmaceutical and biotechnology companies to facilitate the optimisation of future antibody-based therapeutics.</gtr:abstractText><gtr:fund><gtr:end>2013-02-28</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2012-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>140098</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novozymes Biopharma UK ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Novozymes</gtr:description><gtr:id>8949F50D-44EE-4CBD-AD82-C0D24CE0DE45</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partnerContribution>Novozymes are providing funds (contractually confidential) and are also carrying out proof of concept experiments as part of the collaboration.</gtr:partnerContribution><gtr:piContribution>Option and evaluation agreement signed between Novozymes and UCL Business to exploit our protein conjugation technology for the development of albumin conjugates for therapy. Our role is to provide the expertise on the use of next generation maleimides for protein conjugation.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>In this project we demonstrated new methods for the generation of homogeneous anibody fragment and full antibody conjugates. These methods are extremely promising for the generation of superior antibody conjugates for therapeutic applications. This possibility is currently being explored by us (and others) for use in the area of antibody-drug conjugates, as highly targetted 'magic-bullet' therapeutics.</gtr:description><gtr:firstYearOfImpact>2013</gtr:firstYearOfImpact><gtr:id>D59ABA79-DE6C-423C-A6C8-48BDBE8BC00F</gtr:id><gtr:impactTypes/><gtr:sector>Chemicals,Healthcare</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Licensed technology for use on serum stabilisation of drugs, by conjugation to albumin. Albumedix (previously Nozozymes) are licensees.</gtr:description><gtr:id>86CF19D7-63B0-4DFC-81A7-9257AFC491D1</gtr:id><gtr:impact>Ongoing evaluations with other companies in biopharmaceutical area.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO/2011/018611</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Licensed technology</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Key exemplification carried out on patent application. The discovery is that our reagents can carry out highly efficient and selective conjugation of antibodies, leading to prospective application in superior antibody-drug conjugates as therapeutics.</gtr:description><gtr:id>80423BC7-4DF2-47AC-AA16-5D76865AF601</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO/2013/132268 	</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>CHEMICAL MODIFICATION OF ANTIBODIES</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>Using antibodies as therapeutics and diagnostics is one of the most promising areas of research into new healthcare products. Antibodies represent the fastest growing class of therapeutics, with over 30 approved for clinical use to date and
over 150 in clinical development. It is estimated that the global market for antibody therapeutics is currently around $50 billion. Aparticularly promising class of antibody based therapeutics are antibody-drug-conjugates (ADCs), commonly referred to as 'magic-bullet' therapies due to their ability to seek and destroy just diseased cells
within the body (e.g. cancer cells). However, a major hindrance to the area is the lack of suitable chemical methods for the
construction of homogeneous, well defined, antibody conjugates. 
 In this project we developed a new platform for homogeneous antibody conjugation, which we expect to offer major advantages in the construction of next geneation antibody conjugates as therapetics. This was achieved by the design, synthesis and successful application. of a range of new reagents which target specific amino-acid residues present in antibodies.</gtr:description><gtr:exploitationPathways>The development of defined antibody conjugates by this research provides an improved method for generating antibody conjugates as therapeutics and also diagnostics. This should lead to improved healthcare products e.g. better tolerated therapies, improved therapeutic index, more sensitive diagnostic methods and more reproducible/economical products.</gtr:exploitationPathways><gtr:id>59CE0F11-EB35-4E38-8998-A43173883019</gtr:id><gtr:sectors><gtr:sector>Chemicals,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>In this project we developed a range of new reagents for application in antibody conjugation. These included reagents of the type; dibromomaleimide-linker-fluorophore, dibromomaleimide-linker-PEG and dibromomaleimide-linker-fluorophore, and thiophenolmaleimide versions of these reagents. The methodology we developed involved employing these reagents to react with reduced disulfide bonds in antibody fragments and antibodies, affording antibody conjugates which retained the interchain covalent bridges. In this way we were able to generate superior antibody conjugates to those accessible by the current state-of-the-art methods (targeting lysine residues, or reduced disulfide bonds without re-bridging). This methodology has highly significant potential for widespread use in the generation of the next generation of antibody conjugates.</gtr:description><gtr:id>6C7CE7A4-3402-4449-91CD-E8F40ACF9A66</gtr:id><gtr:impact>Not applicable yet</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>New reagents for antibody conjugation</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://dx.doi.org/10.1038/srep01525</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Thiologics</gtr:companyName><gtr:description>In 2011 Dr James Baker co-founded Thiologics (www.thiologics.com), to provide a vehicle to translate the Next Generation Maleimide platform for homogeneous protein conjugation towards clinical product development. ThioLogics is a company formed by UCL Business (UCLB) and is in an early pre-seed phase of development supported solely by UCLB funds. The formation of ThioLogics has created a market presence and facilitated early engagement through our existing networks.</gtr:description><gtr:id>F9036CE9-E5F0-4127-B316-77B3A78095B9</gtr:id><gtr:impact>N/A</gtr:impact><gtr:url>http://www.thiologics.com/</gtr:url><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5FE3D1EE-2619-4D30-9903-92BF80AD1981"><gtr:id>5FE3D1EE-2619-4D30-9903-92BF80AD1981</gtr:id><gtr:title>Reversible protein affinity-labelling using bromomaleimide-based reagents.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d43f6317216d682c0273e0b517a5711f"><gtr:id>d43f6317216d682c0273e0b517a5711f</gtr:id><gtr:otherNames>Nathani RI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54652E5A-D1E3-4019-8564-3C0A22CC1277"><gtr:id>54652E5A-D1E3-4019-8564-3C0A22CC1277</gtr:id><gtr:title>Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/585b5a0d18d3edf2e7afcf5be81e492d"><gtr:id>585b5a0d18d3edf2e7afcf5be81e492d</gtr:id><gtr:otherNames>Schumacher FF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/920C5170-A2A3-4A28-83C3-1C647AB6E999"><gtr:id>920C5170-A2A3-4A28-83C3-1C647AB6E999</gtr:id><gtr:title>Homogeneous bispecifics by disulfide bridging.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9cd3839f08dffd9048d1f4b0f015d023"><gtr:id>9cd3839f08dffd9048d1f4b0f015d023</gtr:id><gtr:otherNames>Hull EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/59326991-C50D-4395-995F-A71A93A17471"><gtr:id>59326991-C50D-4395-995F-A71A93A17471</gtr:id><gtr:title>Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9014725a4043fa2b369fd3b0daf0e550"><gtr:id>9014725a4043fa2b369fd3b0daf0e550</gtr:id><gtr:otherNames>Casta?eda L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E52687F3-5B41-46B3-BD2A-4EF9B2B4633A"><gtr:id>E52687F3-5B41-46B3-BD2A-4EF9B2B4633A</gtr:id><gtr:title>Homogeneous antibody fragment conjugation by disulfide bridging introduces 'spinostics'.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/585b5a0d18d3edf2e7afcf5be81e492d"><gtr:id>585b5a0d18d3edf2e7afcf5be81e492d</gtr:id><gtr:otherNames>Schumacher FF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1DF39C33-39D7-48A5-921C-175C1B48F6DA"><gtr:id>1DF39C33-39D7-48A5-921C-175C1B48F6DA</gtr:id><gtr:title>A mild synthesis of N-functionalised bromomaleimides, thiomaleimides and bromopyridazinediones.</gtr:title><gtr:parentPublicationTitle>Tetrahedron letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9014725a4043fa2b369fd3b0daf0e550"><gtr:id>9014725a4043fa2b369fd3b0daf0e550</gtr:id><gtr:otherNames>Casta?eda L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0040-4039</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/J010448/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>